Raúl Rincón

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7456595/publications.pdf

Version: 2024-02-01

21 534 11 21 papers citations h-index g-index

21 21 21 1112 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential. Molecular Cancer Therapeutics, 2014, 13, 938-947.	4.1	109
2	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget, 2015, 6, 4299-4314.	1.8	87
3	Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2015, 21, 347-356.	7.0	63
4	Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer. Oncotarget, 2014, 5, 196-210.	1.8	36
5	Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. Oncotarget, 2015, 6, 5903-5917.	1.8	35
6	Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1823-1829.	3.8	34
7	UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition. Journal of Clinical Medicine, 2019, 8, 560.	2.4	25
8	Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. British Journal of Cancer, 2014, 110, 2700-2707.	6.4	23
9	Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. Journal of Surgical Oncology, 2014, 110, 484-485.	1.7	22
10	Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. Oncotarget, 2017, 8, 40169-40180.	1.8	20
11	Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer. British Journal of Cancer, 2014, 111, 756-762.	6.4	17
12	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 2780-2790.	4.1	13
13	Combination of KIR2DS4 and Fcl³Rlla polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. Scientific Reports, 2019, 9, 2589.	3.3	9
14	Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance. Cancers, 2021, 13, 2634.	3.7	9
15	Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. Scientific Reports, 2018, 8, 4802.	3.3	8
16	Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer. International Journal of Colorectal Disease, 2014, 29, 641-641.	2.2	7
17	Recent advances and clinical insights into the use of proteomics in the study of atherosclerosis. Expert Review of Proteomics, 2017, 14, 701-713.	3.0	6
18	A comprehensive study of calcific aortic stenosis: from rabbit to human samples. DMM Disease Models and Mechanisms, 2018, 11 , .	2.4	6

#	Article	IF	CITATIONS
19	Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. International Journal of Molecular Sciences, 2015, 16, 19447-19457.	4.1	3
20	Re: Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/Â-Catenin Signaling. Journal of the National Cancer Institute, 2014, 106, dju196-dju196.	6.3	1
21	Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1249-1250.	2.5	1